CASE REPORT

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Hiroshi Hashimoto1*, Kazuyuki Komori1, Koji Kameda1, Shinichi Taguchi1 and Yuichi Ozeki2

Abstract

Background: Anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the therapy of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement. However, its treatment after failure of initial ALK–TKI therapy remains controversial.

Case presentation: A 47-year-old woman with a hemoptysis was diagnosed with adenocarcinoma of the left lung (cT2bN3M0, stage IIIB). Gene mutation analysis indicated positive ALK translocation. Alectinib was selected as the first-line treatment. Although the treatment effect was determined as a partial response, the main tumor regrew. Alectinib was discontinued, and salvage surgery was performed without causing morbidity. The pathological diagnosis was pleomorphic carcinoma without lymph node metastasis (yp-T2bN0). After surgery, lorlatinib was administered as the second-line treatment for 8 months until the patient could not tolerate continuation. Computed tomography scan revealed no lung cancer recurrence 14 months after discontinuation.

Conclusions: Our experience with this case suggests that salvage surgery after alectinib treatment followed by lorlatinib therapy may be effective for initially unresectable ALK-positive NSCLC.

Keywords: Anaplastic lymphoma kinase, Tyrosine kinase inhibitor, Lung cancer, Salvage surgery, Alectinib, Lorlatinib

Background

Although anaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the treatment of locally advanced non-small cell lung cancer (NSCLC) caused by ALK rearrangement [1], its treatment after failure of initial ALK–TKI therapy remains controversial. Here, we report the case of a patient who had ALK-positive locally advanced lung cancer with multiple lymph node metastases and was successfully treated with salvage surgery between the ALK–TKI sequential therapy.
negative epidermal growth factor receptor (EGFR) mutations, c-ros oncogene-1 rearrangement, and v-Raf murine sarcoma viral oncogene homolog B1 mutations. Tumor cells were positive for staining with the ALK antibody, as seen during immunohistochemical analysis (ALK iScore 5 by iAEP immunohistochemistry). ALK break apart fluorescence in situ hybridization verified the occurrence of ALK rearrangement with a rearrangement-positive cell rate of 76.0%. The patient was treated with alectinib, an ALK–TKI. CT scan showed a marked improvement in both the main tumor and metastatic lymph nodes 2 months after the treatment. However, the lung tumor regrew, while the lymph nodes continued to shrink after 6 months of treatment (Fig. 2). Salvage surgery was planned, and left upper lobectomy with mediastinal lymph node dissection was conducted. The hilar region could not be easily expanded due to the presence of bulky mass and strong adhesion around pulmonary artery branch A3 because of prior alectinib treatment; nevertheless, the operation was completed safely. Her postoperative course was uneventful. The pathological diagnosis of the surgical specimen was pleomorphic carcinoma with adenocarcinoma features without any lymph node metastases (ypT3N0M0, stage IIB; Fig. 3). Approximately 50% residual viable tumor cells were found in the primary lesion site (Ef Ib). After salvage surgery, lorlatinib was administered as a second-line ALK–TKI for 8 months until the patient could not tolerate continued therapy because of adverse effects. CT scan revealed no lung cancer recurrence 14 months after discontinuation.

Discussion

ALK rearrangement is detected in 2–5% of NSCLC patients [2]. Crizotinib, an ALK–TKI, has shown clinical efficacy in the treatment of NSCLC with ALK rearrangement [1]. However, most patients develop resistance to crizotinib within 1 year of therapy. Second-generation ALK inhibitors such as alectinib and brigatinib have been developed to overcome resistance to crizotinib. Treatment with these second-generation ALK inhibitors has been well tolerated and has shown efficacy in crizotinib-resistant lung cancers with ALK rearrangement [3]. These ALK inhibitors can also be used as first-line treatment for NSCLC with ALK rearrangement [4].
Lorlatinib, a third-generation ALK inhibitor, has the broadest coverage of ALK resistance mutations that have been identified. It has been a standard treatment option for ALK-positive patients who have experienced failure of one or more ALK inhibitors [5].

Although the mechanisms of acquired resistance to initial ALK–TKIs have been elucidated, treatment methods after failure of initial ALK–TKI therapy remain controversial. Some of the treatment options after initial ALK–TKI treatment failure include ALK sequential therapy (switching to lorlatinib or brigatinib) and cytotoxic chemotherapy with or without immune checkpoint inhibitors.

Salvage surgery has been recognized as a surgical treatment for patients with residual tumors or recurring tumors even after definitive chemotherapy and/or radiation therapy.

Shimizu et al. [6] reported that salvage surgery for NSCLC patients after chemoradiotherapy and conventional radiotherapy can cause minimal complications and reasonable outcomes in selected patients. Their patients’ 3-year overall survival (OS) is 67.3%, and the overall 30- and 90-day mortality are 0 and 0.9%, respectively [6]. Although salvage surgery is a feasible therapeutic modality for advanced NSCLC, its survival benefits remain unclear. To date, some salvage surgery trials have been attempted. Ohtaki et al. [7] reported that salvage surgery after TKI treatment may be beneficial for NSCLC patients. They included 36 patients who underwent TKI treatment followed by salvage surgery [7]. They obtained grade 3 adverse events, 3 year OS, and 90 day mortality of 5.6, 75.1, and 0%, respectively. However, many of these patients’ driver gene alterations were EGFR mutations. Only three patients had ALK rearrangement.

We have done research on PubMed and also looked up on the internet using lung cancer, ALK, and salvage surgery as key words. Several reports have also described salvage surgery for initially unresectable NSCLC treated with ALK–TKIs [8, 9]. To the best of our knowledge, this report is the first to indicate that salvage surgery after first-line ALK–TKI treatment and subsequent switching to second-line ALK–TKI is effective in a patient with ALK-rearranged locally advanced pleomorphic carcinoma of the lungs. Our patient was first treated with alectinib for 6 months. The lung tumor regrew, while the metastatic lymph nodes exhibited remarkable improvement. The therapeutic response showed a dissociation between the main lung tumor and the metastatic lymph nodes. Salvage surgery was planned, and left upper lobectomy with mediastinal lymph node dissection was performed. Subsequently, second-line ALK–TKI lorlatinib...
was administered for 8 months, and no evidence of recurrence was found 22 months after salvage surgery. Ohtaki et al. [7] showed the possible benefits of salvage surgery after TKI treatment; however, recurrence-free survival after surgery was only 22%. Such findings suggested that initially unresectable mutation-positive NSCLCs were still systemic diseases even after salvage surgery and postoperative systemic therapy was important for managing the patients. Some postoperative treatment options include restarting initial TKI treatment, using other TKIs, and administering cytotoxic chemotherapy. In our case, lorlatinib was selected as postoperative therapy because of its efficacy after failure of a first-line, second-generation ALK–TKI.

Our case suggested that salvage surgery after first-line ALK–TKI treatment followed by second-line ALK–TKI provides a favorable clinical benefit to the treatment of patients with ALK-rearranged locally advanced NSCLC.

**Conclusions**

Our experience with this case suggests that salvage surgery after alectinib treatment followed by lorlatinib therapy may be effective for initially unresectable ALK-positive NSCLC.

**Abbreviations**

ALK: Anaplastic lymphoma kinase; TKI: Tyrosine kinase inhibitor; NSCLC: Non-small cell lung cancer; CT: Computed tomography; TTF-1: Thyroid transcription factor-1; EGFR: Epidermal growth factor receptor; OS: Overall survival.

**Acknowledgements**

The authors would like to thank Hideyuki Shimazaki and Susumu Matsukuma for their advice on the pathological findings.

**Authors’ contributions**

Hiroshi Hashimoto conceived and designed the study and drafted the manuscript. Authors other than Hiroshi Hashimoto contributed to the collection, analysis, and interpretation of data. Koji Kameda and Kazuyuki Komori treated the patient. All authors have read and approved the final manuscript. Hiroshi Hashimoto has the overall responsibility and guarantees the scientific integrity of the report. All authors read and approved the final manuscript.
Funding
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for the publication of this case report and any accompanying images was obtained from the patient.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Thoracic Surgery, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama 359-8513, Japan. 2 Department of Thoracic Surgery, Tokorozawa Meisei Hospital, 5095, Yamanuchi, Tokorozawa, Saitama 359-1145, Japan.

Received: 31 January 2022   Accepted: 22 March 2022
Published online: 02 April 2022

References
1. Kwak EL, Bang Y, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. First-Line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2010;363:1693–703. https://doi.org/10.1056/nejmoa1408440.
2. Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study. Cancer. 2014;120:1471–81. https://doi.org/10.1002/cncr.28604.
3. Shaw AT, Gandhi S, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234–42. https://doi.org/10.1016/S1470-2045(15)00488-X.
4. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38. https://doi.org/10.1056/NEJMoai704795.
5. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-negative non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654–67. https://doi.org/10.1016/S1470-2045(18)30649-1.
6. Shimizu K, Ohtaki Y, Suzuki K, Date H, Yamashita M, Iizasa T, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Ann Thorac Surg. 2021;112:862–73. https://doi.org/10.1016/j.athoracsur.2020.10.035.
7. Ohtaki Y, Shimizu K, Suzuki H, Suzuki K, Tsuibo M, Mitsudomi T, et al. Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer. 2021;153:108–16. https://doi.org/10.1016/j.lungcancer.2020.12.037.
8. Horio Y, Mizuno T, Sakao Y, Inaba Y, Yatabe Y, Hida T. Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases. Respir Int Case Rep. 2019;7: e00451. https://doi.org/10.1022/rcr2.451.
9. Iwamoto N, Matsuura Y, Ninomiya H, Uchibori K, Yanagitani N, Hashimoto K, et al. Comparison of salvage surgeries for lung adenocarcinoma treated with anaplastic lymphoma kinase-tyrosine kinase inhibitors. Current Problems in Cancer. Case Rep. 2021;4:10089. https://doi.org/10.1016/j.cpccr.2021.10.0089.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.